Literature DB >> 15494306

Selective regulation of vitamin D receptor-responsive genes by TFIIH.

Pascal Drané1, Emmanuel Compe, Philippe Catez, Pierre Chymkowitch, Jean-Marc Egly.   

Abstract

Mutations in the XPD subunit of the transcription/repair factor TFIIH cause the Xeroderma pigmentosum disorder. We show that in some XP-D deficient cells, transactivation by the vitamin D receptor (VDR) is selectively inhibited for a subset of responsive genes, such as CYP24, and that the XPD/R683W mutation prevents VDR recruitment on its promoter. Contrary to other nuclear receptors, VDR, which lacks a functional A/B domain, is not phosphorylated and consequently not regulated by the cdk7 kinase of TFIIH. In fact, we demonstrate that the VDR transactivation defect resides in Ets1, another activator that cannot be phosphorylated by TFIIH in XP-D cells. Indeed, the phosphorylated Ets1 seems to promote the binding of VDR to its responsive element and trigger the subsequent recruitment of coactivators and RNA pol II. We propose a model in which TFIIH regulates the activity of nuclear receptors by phosphorylating either their A/B domain or an additional regulatory DNA binding partner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494306     DOI: 10.1016/j.molcel.2004.10.007

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  27 in total

1.  The vitamin D receptor: a tumor suppressor in skin.

Authors:  Daniel David Bikle
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

2.  The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3.

Authors:  Pascal Drané; Khalid Ouararhni; Arnaud Depaux; Muhammad Shuaib; Ali Hamiche
Journal:  Genes Dev       Date:  2010-05-26       Impact factor: 11.361

3.  Increased apoptosis, p53 up-regulation, and cerebellar neuronal degeneration in repair-deficient Cockayne syndrome mice.

Authors:  R R Laposa; E J Huang; J E Cleaver
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 4.  Hot topics in DNA repair: the molecular basis for different disease states caused by mutations in TFIIH and XPG.

Authors:  Orlando D Schärer
Journal:  DNA Repair (Amst)       Date:  2008-02-01

Review 5.  TFIIH: when transcription met DNA repair.

Authors:  Emmanuel Compe; Jean-Marc Egly
Journal:  Nat Rev Mol Cell Biol       Date:  2012-05-10       Impact factor: 94.444

6.  Heat stress phenotypes of Arabidopsis mutants implicate multiple signaling pathways in the acquisition of thermotolerance.

Authors:  Jane Larkindale; Jennifer D Hall; Marc R Knight; Elizabeth Vierling
Journal:  Plant Physiol       Date:  2005-05-27       Impact factor: 8.340

7.  Abnormal XPD-induced nuclear receptor transactivation in DNA repair disorders: trichothiodystrophy and xeroderma pigmentosum.

Authors:  Xiaolong Zhou; Sikandar G Khan; Deborah Tamura; Takahiro Ueda; Jennifer Boyle; Emmanuel Compe; Jean-Marc Egly; John J DiGiovanna; Kenneth H Kraemer
Journal:  Eur J Hum Genet       Date:  2012-12-12       Impact factor: 4.246

8.  ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities.

Authors:  Wassim Abdulrahman; Izarn Iltis; Laura Radu; Cathy Braun; Anne Maglott-Roth; Christophe Giraudon; Jean-Marc Egly; Arnaud Poterszman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6.

Authors:  Rimpi K Saini; Ichiro Kaneko; Peter W Jurutka; Ryan Forster; Antony Hsieh; Jui-Cheng Hsieh; Mark R Haussler; G Kerr Whitfield
Journal:  Calcif Tissue Int       Date:  2012-12-22       Impact factor: 4.333

10.  Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients.

Authors:  Takahiro Ueda; Emmanuel Compe; Philippe Catez; Kenneth H Kraemer; Jean-Marc Egly
Journal:  J Exp Med       Date:  2009-11-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.